In the quest to combat age-related neurodegenerative conditions, researchers are making strides towards mRNA therapies capable of breaking down harmful intracellular protein aggregates. By delivering synthetic mRNA into cells using lipid nanoparticles, gene therapy development is actively exploring ways to produce proteins that can address biochemical issues within aged tissues, such as the clearance of protein aggregates. These mRNA therapies offer short-term expression of therapeutic proteins, making them ideal for targeting accumulated damage that requires intermittent treatment. The focus is on addressing tau proteins inside neurons, as current therapies mainly target aggregates outside of cells, leaving the harmful intracellular tau untouched. Scientists are exploring the use of mRNA technology to deliver instructions for tau-targeting intrabodies directly into neurons, allowing cells to produce active antibodies internally. While still in the early stages, this research shows promise in the fight against age-related protein aggregates.
Rejuvenation biotechnologies targeting aberrant tau are in development, ranging from early cell studies to Phase III clinical trials. The ambition to clear tau aggregates began as a response to skepticism about beta-amyloid’s role in Alzheimer’s disease. While early attempts faced challenges, current clinical trials are testing therapies targeting tau, with a focus on clearing aberrant tau inside neurons. This approach shows potential in reducing the burden of soluble tau in the brain. By utilizing mRNA technology to deliver intrabodies, researchers aim to develop a new approach to combat neurodegenerative diseases associated with protein aggregates.
Link: https://www.sens.org/get-the-message-mrna-to-target-intracellular-aggregates/
